NEWS & MEDIA
Featured
ASX News
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Corporate Spotlight
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
Corporate Spotlight
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
ASX News
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...
ASX News
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field...
ASX News
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...
ASX News
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...
ASX News
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...
ASX News
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...
ASX News
Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product
Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to...
ASX News
Investor Briefing – TheraPharm GmbH Acquisition
Melbourne (Australia) – 1st December 2020. Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition
ASX News
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH
Melbourne (Australia) and Baar (Switzerland) – 30th November 2020. Telix announces it has entered into an agreement with Scintec Diagnostics...
ASX News
Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...